Business Segments · Total Assets
Neuroscience — Total Assets
Medtronic Neuroscience — Total Assets decreased by 0.2% to $18.45B in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ2 2020
Last reportedQ1 2026
Rolls up toTotal Assets
How to read this metric
An increase suggests capital investment for growth, while a decrease may indicate asset divestiture or improved capital efficiency.
Detailed definition
This represents the total value of assets specifically attributed to the Neuroscience segment, including inventory, prop...
Peer comparison
Comparable to segment asset disclosures in annual reports of diversified healthcare manufacturers.
Metric ID:
mdt_segment_neuroscience_total_assetsHistorical Data
8 periods
| Q2 '21 | Q2 '22 | Q2 '23 | Q2 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $17.15B | $16.92B | $18.35B | $18.27B | $18.48B | $18.43B | $18.48B | $18.45B |
| QoQ Change | — | -1.4% | +8.4% | -0.4% | +1.1% | -0.2% | +0.2% | -0.2% |
| YoY Change | — | -1.4% | +8.4% | -0.4% | +1.1% | — | — | — |
Range$16.92B – $18.48B
CAGR+4.3%
Avg YoY Growth+1.9%
Median YoY Growth+0.4%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Medtronic's neuroscience — total assets?
- Medtronic (MDT) reported neuroscience — total assets of $18.45B in Q1 2026.
- What does neuroscience — total assets mean?
- The total value of all assets used by the neuroscience business unit.